Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease systemic scleroderma
Symptom C0206062|interstitial lung disease
Sentences 36
PubMedID- 23697634 Background: to determine the usefulness of ca 15.3 as a candidate biomarker in systemic sclerosis (ssc) patients with interstitial lung disease (ild).
PubMedID- 22084615 Reduced hypoxia risk in a systemic sclerosis patient with interstitial lung disease after long-term pulmonary rehabilitation.
PubMedID- 23824244 Pulmonary hypertension (ph) is a well-known complication of systemic sclerosis and together with interstitial lung diseases is the leading cause of ssc-related deaths.
PubMedID- 22610787 Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
PubMedID- 22972016 Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
PubMedID- 23940607 Lung fibrosis is a common trait of idiopathic pulmonary fibrosis (ipf) and systemic sclerosis (ssc) with interstitial lung disease (ild).
PubMedID- 21458128 Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
PubMedID- 23401350 Does c-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis.
PubMedID- 25282395 Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (ssc-ild): efficacy of maintenance immunosuppression in responders and non-responders.
PubMedID- 23588945 Can serum surfactant protein d or cc-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis.
PubMedID- 21996293 Increased frequency of circulating th22 in addition to th17 and th2 lymphocytes in systemic sclerosis: association with interstitial lung disease.
PubMedID- 26370615 Pulmonary fibrosis is a common characteristic of ipf and systemic sclerosis with interstitial lung disease (ssc-ild)7; however, the most common histological pattern observed in ipf is usual interstitial pneumonia (uip), while the pattern most commonly observed in ssc-ild is nonspecific interstitial pneumonia (nsip)8. there is some controversy regarding the pathophysiology of uip and nsip.
PubMedID- 21474572 Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
PubMedID- 22015621 Intravenous cyclophosphamide pulse therapy (ivcy) exerts its efficacy against interstitial lung disease (ild) associated with systemic sclerosis (ssc) by restoring vascular injuries as well as aberrant immune activation.
PubMedID- 25629053 Objective: to evaluate the performance of a computerized-aided method (cam) for quantification of interstitial lung disease (ild) in patients with systemic sclerosis and to determine its correlation with the conventional visual reader-based score (covr) and the pulmonary function tests (pfts).
PubMedID- 22540429 Serum levels of adam12-s: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.
PubMedID- 25356253 Twenty systemic sclerosis patients with associated interstitial lung disease were treated with imatinib (up to 600 mg/day).
PubMedID- 20404807 Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
PubMedID- 24801572 The aim of this study was to evaluate efficacy of azathioprine (aza) and cyclophosphamide (cyc) as a therapeutic regimen for interstitial lung disease associated with systemic sclerosis (ssc).
PubMedID- 24814462 Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.
PubMedID- 23925736 Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
PubMedID- 21538327 systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
PubMedID- PMC3329084 These findings suggest that the development of pulmonary arterial hypertension is probably independent of the existence of interstitial lung disease in patients with systemic sclerosis.
PubMedID- 25624597 Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis.
PubMedID- 25665185 Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.
PubMedID- 23660398 Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
PubMedID- 25650330 Introduction: interstitial lung disease occurs frequently in patients with systemic sclerosis (ssc).
PubMedID- 21978705 systemic sclerosis (ssc) is associated with interstitial lung diseases.
PubMedID- 23378460 Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
PubMedID- 24838199 Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct.
PubMedID- 24205063 We investigated whether partitioning dlco into membrane conductance for co (dmco) and pulmonary capillary blood volume (vcap) was helpful in suspecting precapillary pulmonary (arterial) hypertension (p(a)h) in systemic sclerosis (ssc) patients with or without interstitial lung disease (ild).
PubMedID- 26315813 Objectives: to evaluate a new ultrasound sign, pleural irregularity (pi), for the study of interstitial lung disease (ild) in patients with systemic sclerosis (ssc) and antisynthetase syndrome (ass).
PubMedID- 26392856 We discuss a case that demonstrates the difficulties in making a confident diagnosis of interstitial lung disease (ild) associated with systemic sclerosis (ssc).
PubMedID- 23764864 Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
PubMedID- 25709096 Where are we going in the management of interstitial lung disease in patients with systemic sclerosis.
PubMedID- 26079155 Exhaled nitric oxide (no) is increased as a result of lung inflammation, which in turn causes subsequent interstitial lung disease in patients with systemic sclerosis (ssc).

Page: 1